FDA grants marketing approval for ripretinib (Qinlock) for 4th line treatment of advanced gastrointestinal stromal tumours

Approval for this kinase inhibitor is based on positive results from INVICTUS phase 3 study in 129 patients, whose previous therapies have included at least imatinib, sunitinib, and regorafenib, which achieved primary endpoint of improved PFS (6.3 vs 1.0 months with placebo).


US Food and Drug Administration